Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE2.9500
- TODAY'S CHANGE (%)0.0200 (0.6826%)
- Bid / Lots2.9500/ 6
- Ask / Lots3.0900/ 1
- Open / Previous Close2.9400 / 2.9300
- Day Range
- 52 Week Range
- Volume239,459
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 2311 | 2.89 |
| 09:34 ET | 1900 | 2.91 |
| 09:36 ET | 571 | 2.96 |
| 09:38 ET | 4778 | 2.96 |
| 09:39 ET | 200 | 2.9352 |
| 09:41 ET | 600 | 2.96 |
| 09:43 ET | 2000 | 2.9501 |
| 09:45 ET | 850 | 2.95 |
| 09:50 ET | 3500 | 2.96 |
| 09:52 ET | 1100 | 2.96 |
| 09:54 ET | 364 | 2.9599 |
| 09:56 ET | 2386 | 2.97 |
| 09:57 ET | 2880 | 2.97 |
| 10:01 ET | 1664 | 3.005 |
| 10:03 ET | 2200 | 3 |
| 10:06 ET | 4884 | 3.03 |
| 10:08 ET | 137 | 3.02 |
| 10:10 ET | 890 | 3 |
| 10:12 ET | 800 | 3.01 |
| 10:14 ET | 600 | 3.015 |
| 10:15 ET | 2840 | 3.0128 |
| 10:19 ET | 400 | 3.0208 |
| 10:21 ET | 350 | 3.025 |
| 10:24 ET | 500 | 3.025 |
| 10:26 ET | 1300 | 3.04 |
| 10:28 ET | 400 | 3.035 |
| 10:30 ET | 200 | 3.035 |
| 10:32 ET | 1100 | 3.0399 |
| 10:33 ET | 1150 | 3.05 |
| 10:35 ET | 200 | 3.0499 |
| 10:39 ET | 2365 | 3.045 |
| 10:42 ET | 500 | 3.0499 |
| 10:44 ET | 1100 | 3.045 |
| 10:46 ET | 100 | 3.05 |
| 10:48 ET | 3553 | 3.0501 |
| 10:50 ET | 1300 | 3.04 |
| 10:51 ET | 100 | 3.0401 |
| 10:53 ET | 1250 | 3.04 |
| 10:55 ET | 1901 | 3.03 |
| 10:57 ET | 400 | 3.02 |
| 11:00 ET | 2620 | 3.0197 |
| 11:02 ET | 200 | 3.015 |
| 11:04 ET | 300 | 3.015 |
| 11:06 ET | 930 | 3.015 |
| 11:08 ET | 386 | 3.0108 |
| 11:09 ET | 100 | 3.015 |
| 11:11 ET | 1800 | 3.03 |
| 11:13 ET | 800 | 3.0296 |
| 11:18 ET | 1800 | 3.025 |
| 11:20 ET | 1000 | 3.0266 |
| 11:22 ET | 5479 | 3.04 |
| 11:24 ET | 700 | 3.045 |
| 11:26 ET | 500 | 3.045 |
| 11:27 ET | 12600 | 3.055 |
| 11:29 ET | 989 | 3.07 |
| 11:31 ET | 417 | 3.07 |
| 11:33 ET | 300 | 3.07 |
| 11:36 ET | 2680 | 3.05 |
| 11:40 ET | 900 | 3.03 |
| 11:44 ET | 1200 | 3.025 |
| 11:49 ET | 100 | 3.025 |
| 11:51 ET | 4423 | 3.015 |
| 11:54 ET | 300 | 3.015 |
| 11:56 ET | 200 | 3.015 |
| 12:03 ET | 300 | 3.02 |
| 12:05 ET | 100 | 3.01 |
| 12:07 ET | 100 | 3.02 |
| 12:12 ET | 100 | 3.02 |
| 12:18 ET | 100 | 3.02 |
| 12:23 ET | 100 | 3.015 |
| 12:25 ET | 1129 | 3.025 |
| 12:27 ET | 218 | 3.025 |
| 12:30 ET | 200 | 3.03 |
| 12:32 ET | 1100 | 3.025 |
| 12:34 ET | 600 | 3.03 |
| 12:36 ET | 985 | 3.025 |
| 12:38 ET | 667 | 3.025 |
| 12:39 ET | 582 | 3.025 |
| 12:41 ET | 729 | 3.03 |
| 12:43 ET | 300 | 3.025 |
| 12:48 ET | 200 | 3.025 |
| 12:50 ET | 600 | 3.025 |
| 12:52 ET | 300 | 3.025 |
| 12:54 ET | 300 | 3.025 |
| 12:56 ET | 1132 | 3.025 |
| 12:57 ET | 200 | 3.025 |
| 12:59 ET | 1829 | 3.015 |
| 01:01 ET | 100 | 3.01 |
| 01:06 ET | 100 | 3.015 |
| 01:08 ET | 6935 | 3 |
| 01:10 ET | 8828 | 3 |
| 01:14 ET | 100 | 2.995 |
| 01:15 ET | 3300 | 3.015 |
| 01:17 ET | 800 | 3.01 |
| 01:21 ET | 4459 | 3 |
| 01:24 ET | 518 | 2.995 |
| 01:26 ET | 1189 | 2.99 |
| 01:28 ET | 3000 | 3 |
| 01:32 ET | 1000 | 3 |
| 01:35 ET | 300 | 3.01 |
| 01:37 ET | 654 | 3.0036 |
| 01:39 ET | 2100 | 3.005 |
| 01:42 ET | 1260 | 3 |
| 01:50 ET | 100 | 2.995 |
| 01:51 ET | 300 | 3 |
| 01:53 ET | 100 | 3 |
| 01:55 ET | 400 | 2.995 |
| 01:57 ET | 200 | 3 |
| 02:00 ET | 100 | 3 |
| 02:04 ET | 100 | 2.995 |
| 02:06 ET | 300 | 2.995 |
| 02:08 ET | 1757 | 2.985 |
| 02:09 ET | 771 | 2.985 |
| 02:13 ET | 1040 | 2.985 |
| 02:15 ET | 100 | 2.985 |
| 02:18 ET | 100 | 2.988 |
| 02:20 ET | 3662 | 2.985 |
| 02:22 ET | 100 | 2.985 |
| 02:27 ET | 100 | 2.985 |
| 02:29 ET | 200 | 2.99 |
| 02:31 ET | 400 | 2.99 |
| 02:33 ET | 300 | 2.99 |
| 02:36 ET | 200 | 2.99 |
| 02:38 ET | 200 | 2.99 |
| 02:40 ET | 300 | 2.99 |
| 02:42 ET | 4495 | 2.975 |
| 02:44 ET | 754 | 2.965 |
| 02:45 ET | 300 | 2.97 |
| 02:47 ET | 200 | 2.965 |
| 02:49 ET | 475 | 2.9639 |
| 02:56 ET | 2023 | 2.96 |
| 03:00 ET | 2809 | 2.965 |
| 03:02 ET | 436 | 2.975 |
| 03:03 ET | 400 | 2.97 |
| 03:05 ET | 300 | 2.965 |
| 03:09 ET | 762 | 2.97 |
| 03:12 ET | 100 | 2.97 |
| 03:16 ET | 200 | 2.97 |
| 03:18 ET | 100 | 2.965 |
| 03:20 ET | 200 | 2.97 |
| 03:21 ET | 100 | 2.965 |
| 03:23 ET | 750 | 2.97 |
| 03:25 ET | 520 | 2.9695 |
| 03:27 ET | 400 | 2.97 |
| 03:30 ET | 100 | 2.97 |
| 03:32 ET | 1095 | 2.97 |
| 03:34 ET | 100 | 2.965 |
| 03:36 ET | 300 | 2.97 |
| 03:38 ET | 400 | 2.965 |
| 03:39 ET | 300 | 2.965 |
| 03:41 ET | 467 | 2.965 |
| 03:43 ET | 450 | 2.965 |
| 03:45 ET | 1036 | 2.965 |
| 03:48 ET | 2239 | 2.955 |
| 03:52 ET | 711 | 2.965 |
| 03:54 ET | 500 | 2.965 |
| 03:56 ET | 1118 | 2.97 |
| 03:57 ET | 1318 | 2.97 |
| 03:59 ET | 22658 | 2.95 |
May 16, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 11:16AM ET on Thursday May 16, 2024 by Dow Jones
11:16AM ET on Thursday May 16, 2024 by Dow JonesDJ Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham, from 7:33AM ET on Thursday May 16, 2024 by Dow Jones
7:33AM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
Press Release: Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow JonesMereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 413.8M | -11.1x | --- |
Allogene Therapeutics Inc | 525.1M | -1.4x | --- |
Cabaletta Bio Inc | 527.2M | -6.3x | --- |
Altimmune Inc | 519.7M | -4.6x | --- |
Compass Pathways PLC | 511.5M | -3.2x | --- |
Lexeo Therapeutics Inc | 509.3M | -5.7x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $413.8M |
|---|---|
Revenue (TTM) | $9.1M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-0.27 |
Book Value | $0.63 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 45.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
